文献速递治疗药物监测与药物基因组学特殊人群用药

基于计算机模拟的扩展给药方案在单克隆抗体免疫检查点抑制剂中的应用机会

Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.
PubMed 文献 · Br J Clin Pharmacol · 2020-06-11

本文综述了FDA批准的PD-1、PD-L1/2和CTLA-4抑制剂的适应证和当前推荐剂量,并讨论了利用治疗药物监测(TDM)结合贝叶斯方法和药代动力学模拟来优化扩展给药方案的潜力。除帕博利珠单抗外,其他PD-1/PD-L1抑制剂在广泛评估的剂量下显示暴露-反应曲线平台期以及药物暴露的时间依赖性变化,应答者药物清除率随时间下降更明显,可能产生超治疗浓度。通过频繁 trough 测量和模拟可估计个体清除率并设计替代给药策略以降低药物和经济负担,同时维持治疗水平。

要点

  • 多数PD-1/PD-L1抑制剂在评估剂量下暴露-反应曲线呈平台期,提示TDM优化给药可行。
  • 应答者药物清除率随时间下降更明显,可能导致超治疗浓度。
  • 贝叶斯方法结合trough测量可估计个体清除率,模拟替代给药方案。

核心结论

  • 对PD-1/PD-L1抑制剂开展TDM研究可能合理,以降低成本并可能减轻免疫相关不良事件的严重程度和/或持续时间。

研究设计与样本

  • 本文为综述,讨论FDA批准的PD-1、PD-L1/2和CTLA-4抑制剂的适应证和当前推荐剂量,以及支持TDM策略研究的证据。

主要发现

  • 除帕博利珠单抗外,其他PD-1和PD-L1抑制剂(纳武利尤单抗、西米普利单抗-rwlc、阿替利珠单抗、阿维鲁单抗、度伐利尤单抗)在广泛评估的剂量下显示暴露-反应曲线平台期。
  • 这些药物显示药物暴露的时间依赖性变化。
  • 应答者药物清除率随时间下降更明显,因此可能具有超治疗血清浓度。

临床怎么用

  • 通过频繁 trough 测量,可利用药代动力学建模和模拟通过贝叶斯方法估计药物清除率。
  • 基于患者特异性清除率估计,可模拟最佳替代给药策略以降低药物和经济负担,同时维持治疗水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic drug monitoring (TDM) involves frequent measurements of drug concentrations to ensure levels remain within a therapeutic window, and it is especially useful for drugs with narrow therapeutic indices or extensive interindividual pharmacokinetic variability. This technique has never been applied to immuno-oncology drugs, but, given recent examinations of clinical data (both exposure and response) on a number of these drugs, further investigations into TDM may be justified to reduce costs as well as potentially reducing the severity and/or duration of immune-related adverse events. Specifically, all but one of the approved PD-1 and PD-L1 inhibitors (pembrolizumab, nivolumab, cemiplimab-rwlc, atezolizumab, avelumab, durvalumab) have been shown to exhibit a plateaued exposure-response (E-R) curve at doses evaluated extensively to date, as well as time-dependent changes in drug exposure. Furthermore, responders have a greater decrease in drug clearance over time and would, therefore, have supratherapeutic serum concentrations. With frequent trough measurements, it is possible to use pharmacokinetic modelling and simulation to estimate drug clearance via Bayesian methods. Based on patient-specific estimates for clearance, optimal alternative dosing strategies can be simulated to lower drug and cost burden yet maintain therapeutic levels, especially as the clearance of the drug decreases over time. This review will comprehensively discuss each of the FDA approved PD-1, PD-L1/2 and CTLA-4 inhibitors regarding their indications and current recommended dosing, with evidence supporting the investigation of these types of TDM strategies.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Peer CJ, Goldstein DA, Goodell JC, et al. Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. Br J Clin Pharmacol. 2020. PMID: 32424951. doi:10.1111/bcp.14369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。